Ramos-Nino Maria E, MacLean Charles D, Littenberg Benjamin
Department of Microbiology, Immunology, and Pharmacology, St. George's University, West Indies, Grenada.
Department of Pathology and Laboratory Medicine, University of Vermont 05401, Burlington, VT, USA.
Asthma Res Pract. 2021 May 28;7(1):6. doi: 10.1186/s40733-021-00073-1.
The association of obesity with the development of obstructive lung disease, namely asthma and/or chronic obstructive pulmonary disease, has been found to be significant in general population studies, and weight loss in the obese has proven beneficial in disease control. Obese patients seem to present with a specific obstructive lung disease phenotype including a reduced response to corticosteroids. Obesity is increasingly recognized as an important factor to document in obstructive lung disease patients and a critical comorbidity to report in diabetic patients, as it may influence disease management. This report presents data that contributes to establishing the relationship between obstructive lung disease in a diabetic cohort, a population highly susceptible to obesity.
A total of 1003 subjects in community practice settings were interviewed at home at the time of enrolment into the Vermont Diabetes Information System, a clinical decision support program. Patients self-reported their personal and clinical characteristics, including any history of obstructive lung disease. Laboratory data were obtained directly from the clinical laboratory, and current medications were obtained by direct observation of medication containers. We performed a cross-sectional analysis of the interviewed subjects to assess a possible association between obstructive lung disease history and obesity.
In a multivariate logistic regression model, a history of obstructive lung disease was significantly associated with obesity (body mass index ≥30) even after correcting for potential confounders including gender, low income (<$30,000/year), number of comorbidities, number of prescription medications, cigarette smoking, and alcohol problems (adjusted odds ratio (OR) = 1.58, P = 0.03, 95% confidence interval (CI) = 1.05, 2.37). This association was particularly strong and significant among female patients (OR = 2.18, P = < 0.01, CI = 1.27, 3.72) but not in male patients (OR = 0.97, P = 0.93, CI = 0.51, 1.83).
These data suggest an association between obesity and obstructive lung disease prevalence in patients with diabetes, with women exhibiting a stronger association. Future studies are needed to identify the mechanism by which women disproportionately develop obstructive lung disease in this population.
在一般人群研究中,已发现肥胖与阻塞性肺病(即哮喘和/或慢性阻塞性肺疾病)的发生显著相关,且肥胖者体重减轻已证明对疾病控制有益。肥胖患者似乎呈现出一种特定的阻塞性肺病表型,包括对皮质类固醇的反应降低。肥胖越来越被认为是阻塞性肺病患者需要记录的一个重要因素,以及糖尿病患者需要报告的一种关键合并症,因为它可能影响疾病管理。本报告提供的数据有助于确立糖尿病队列(一个极易肥胖的人群)中阻塞性肺病之间的关系。
在纳入佛蒙特糖尿病信息系统(一个临床决策支持项目)时,对社区实践环境中的1003名受试者进行了家访。患者自行报告其个人和临床特征,包括任何阻塞性肺病病史。实验室数据直接从临床实验室获取,当前用药情况通过直接观察药瓶获得。我们对受访受试者进行了横断面分析,以评估阻塞性肺病病史与肥胖之间的可能关联。
在多变量逻辑回归模型中,即使在校正了包括性别、低收入(<30,000美元/年)、合并症数量、处方药数量、吸烟和酒精问题等潜在混杂因素后,阻塞性肺病病史仍与肥胖(体重指数≥30)显著相关(调整后的优势比(OR)=1.58,P=0.03,95%置信区间(CI)=1.05,2.37)。这种关联在女性患者中尤为强烈且显著(OR=2.18,P<0.01,CI=1.27,3.72),但在男性患者中不显著(OR=0.97,P=0.93,CI=0.51,1.83)。
这些数据表明糖尿病患者中肥胖与阻塞性肺病患病率之间存在关联,女性的关联更强。未来需要开展研究以确定该人群中女性患阻塞性肺病比例过高的机制。